Simulations Plus, Inc.
$18.50$0.00 (0.0%)
Last close · Data as of Oct 7, 2026
- Market cap
- $336.4M
- P/E
- -5.2x
- EV / EBITDA
- 20.8x
- Revenue
- $79.2M
- Net margin
- -81.7%
- ROCE
- 5.2%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 7 Oct 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change $0.00 (0.0%) from $18.50 to $18.50 · Last close Oct 7, 2026
Best weekday to invest, historically
The same weekly amount in SLP, bought on each weekday since 2021.
News & filings
What Simulations Plus filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 64.7 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are 7.67 times current liabilities.
- Prices are as of 7 Oct 2026; price-based points are paused until newer prices arrive.
Prices to the 7 Oct 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments.
Read moreShow less
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
- Sector
- Healthcare
- Shares outstanding
- 20.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $336.4M
- P/E
- -5.2x
- P/B
- 2.7x
- EV / EBITDA
- 20.8x
- EV / Sales
- 3.9x
- P/S
- 4.2x
- 52-week high
- $20.84
- 52-week low
- $11.36
Profitability
- Operating margin
- 8.2%
- Net margin
- -81.7%
- EBITDA margin
- 18.6%
- ROE
- -51.9%
- ROCE
- 5.2%
- ROIC
- 5.4%
- ROA
- -49.1%
- Asset turnover
- 0.60
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $79.2M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 13.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 13.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -750.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $14.4M
Solvency
- Current ratio
- 7.67
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- -0.28
- Cash / Market cap
- 9.2%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $79.2M |
| Cost of revenue | $33.0M |
| Gross profit | $46.2M |
| Operating expenses | $39.7M |
| Research and development | $6.9M |
| Selling, general and administrative | $32.8M |
| Operating income | $6.5M |
| Interest and other | -$75.9M |
| Pretax income | -$69.4M |
| Tax and other | -$4.7M |
| Net income | -$64.7M |
Revenue and net profit
Revenue grew 13.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $53.9M | $12.5M |
| FY2023 | $59.6M | $10.0M |
| FY2024 | $70.0M | $10.0M |
| FY2025 | $79.2M | -$64.7M |
Cash flows
FY2025: $18.1M from operations, $14.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $17.9M | $13.9M |
| FY2023 | $21.9M | $17.6M |
| FY2024 | $13.3M | $9.0M |
| FY2025 | $18.1M | $14.4M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $79.2M+13.1%1Y
- EBITDA
- $14.7M+24.6%1Y
- Net profit
- -$64.7M-750.2%1Y
- Cash from operations
- $18.1M+36.1%1Y
- Free cash flow
- $14.4M+59.7%1Y
- Revenue CAGR, 3Y
- 13.7%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $79.2M | $14.7M | -$64.7M | $14.4M | -51.9% | +13.1% | -750.2% |
Monthly returns
Month-by-month returns of SLP across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $131.9M |
| Current assets | $51.5M |
| Non-current assets | $80.4M |
| Liabilities | $7.1M |
| Current liabilities | $6.7M |
| Non-current liabilities | $410.0k |
| Equity | $124.8M |
| Paid-in capital | $159.4M |
| Retained earnings | -$34.4M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; SLP highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Atea Pharmaceuticals, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Simulations Plus, Inc.SLPthis company | $336.4M | -5.2x | 2.7x | -51.9% | 20.8x |
| Atea Pharmaceuticals, Inc.AVIR | $353.7M | -2.2x | 1.3x | -57.5% | -1.4x |
| Greenwich LifeSciences, Inc.GLSI | $347.1M | -22.0x | 137.0x | -623.1% | — |
| Larimar Therapeutics, Inc.LRMR | $341.8M | — | 4.4x | -212.2% | — |
| Enanta Pharmaceuticals, Inc.ENTA | $341.1M | -4.2x | 5.3x | -126.5% | -5.1x |
| Verastem, Inc.VSTM | $339.2M | -1.6x | 5.9x | -366.2% | -1.1x |
| 908 Devices Inc.MASS | $333.5M | 17.1x | 2.3x | 13.6% | -12.6x |
| Abeona Therapeutics Inc.ABEO | $331.7M | 4.7x | 2.1x | 44.7% | 3.5x |
| Humacyte, Inc.HUMA | $330.8M | -8.1x | 106.4x | -1313.4% | -15.5x |
| Peer median | — | -2.2x | 4.8x | -169.4% | -3.3x |
Year-to-date ROI
SLP since 1 January, against earlier years.
Historical volatility
SLP's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 27.7% |
| FY2023 | 15.5% |
| FY2024 | 8.8% |
| FY2025 | 8.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $79.2M |
| Cost of revenueCost Of Revenue | $33.0M |
| Gross profitGross Profit | $46.2M |
| Operating expensesOperating Expense | $39.7M |
| Research and developmentResearch And Development | $6.9M |
| Selling, general and administrativeSelling General And Administration | $32.8M |
| Total expensesTotal Expenses | $72.7M |
| Operating incomeOperating Income | $6.5M |
| Interest and other | |
| Pretax incomePretax Income | -$69.4M |
| TaxTax Provision | -$4.7M |
| Net incomeNet Income | -$64.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $131.9M |
| Current assetsCurrent Assets | $51.5M |
| Non-current assetsTotal Non Current Assets | $80.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $7.1M |
| Current liabilitiesCurrent Liabilities | $6.7M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $410.0k |
| EquityTotal Equity Gross Minority Interest | $124.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $18.1M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $18.1M |
| Net income, continuing operationsNet Income From Continuing Operations | -$64.7M |
| Depreciation and amortisationDepreciation And Amortization | $8.2M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $8.2M |
| Amortization of securitiesAmortization Of Securities | -$60.0k |
| Stock-based compensationStock Based Compensation | $6.3M |
| Deferred taxDeferred Tax | -$5.4M |
| Deferred income taxDeferred Income Tax | -$5.4M |
| Operating gains and lossesOperating Gains Losses | $0.00 |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | -$20.0k |
| Asset impairmentAsset Impairment Charge | $77.2M |
| Change in working capitalChange In Working Capital | -$2.6M |
| Other non-cash itemsOther Non Cash Items | -$860.0k |
| Investing cash flowInvesting Cash Flow | $3.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $3.6M |
| Capital expenditureCapital Expenditure | -$3.7M |
| Capital expenditure (reported)Capital Expenditure Reported | -$2.6M |
| Purchase of PP&EPurchase Of PPE | -$710.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$710.0k |
| AcquisitionsPurchase Of Business | $0.00 |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$6.5M |
| Sale of investmentsSale Of Investment | $15.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $8.5M |
| Purchase of intangiblesPurchase Of Intangibles | -$380.0k |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$380.0k |
| Other investing changesNet Other Investing Changes | -$1.2M |
| Financing cash flowFinancing Cash Flow | -$1.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$1.1M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $430.0k |
| Dividends paidCash Dividends Paid | $0.00 |
| Common dividends paidCommon Stock Dividend Paid | $0.00 |
| Other financing chargesNet Other Financing Charges | -$1.6M |
| Change in cashChanges In Cash | $20.5M |
| Cash at the start of the yearBeginning Cash Position | $10.3M |
| Cash at the end of the yearEnd Cash Position | $30.9M |
| Free cash flowFree Cash Flow | $14.4M |
| Supplemental |
Learn while you research
Academy chapters picked for Simulations Plus, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read